Given the well-known features of FABP4 in metabolic disorders and inflammation, blocking or neutralizing FABP4 by either chemical inhibitors or monoclonal antibodies has emerged as a novel therapeutical strategy. This evidence concerns the gene FABP4 and Other metabolic disease.